Clearest explanation I have seen to date on how Pfizer plans to handle its placebo participants. Posted in the FDA EUA decision memo, which seems to have been posted since yesterday (or I missed it before): https://www.fda.gov/media/144416/download

It's a good compromise. Doesn't make participants any worse off, since they'll get vaccinated at latest on same priority schedule as those outside the trial, and still gives some participant reciprocity, since many of us will likely be waiting longer than 6 months.

To be clear, this is not data over lives. Allocating scarce vaccine to people in high priority groups over placebo participants in lower priority groups will save more lives.

Excellent ethical analysis of what turned out to be pretty close to Pfizer's approach here, from @anetrid, @mlipsitch, and Frank Miller. https://jamanetwork.com/journals/jama/fullarticle/2774382